Σύγκριση μεθόδων

	Κλίμακα Ποιότητας Ζωής Σχετιζόμενης με την Υγεία λόγω ΓΟΠ	Δείκτης Καρδιναλικών Συμπτωμάτων Γαστροπάρεσης	Διαγνωστικά Κριτήρια Rome IV για το Σύνδρομο Ευερέθιστου Εντέρου
Πεδίο	Γαστρεντερολογία	Γαστρεντερολογία	Γαστρεντερολογία
Οικογένεια	Process / pipeline	Process / pipeline	Process / pipeline
Έτος προέλευσης	1996	2003	2016
Δημιουργός	Velanovich, V., Zhang, Y., Hollis, J. B., et al.	Revicki, D. A., Rentz, A. M., Dubois, D., et al.	Rome Foundation (multinational expert consensus)
Τύπος	Self-report	Self-report	Diagnostic Criteria
Θεμελιώδης πηγή	Velanovich, V., Zhang, Y., Hollis, J. B., Feldman, M. I., Sampliner, R., Guan, W., & Escamilla, C. (1996). Presenting symptoms and outcome measures in reflux esophagitis. Digestive Diseases and Sciences, 41(10), 1865–1873.	Revicki, D. A., Rentz, A. M., Dubois, D., Kahrilas, P., Stanghellini, V., Talley, N. J., & Tack, J. (2003). Development and validation of a patient-assessed gastroparesis symptom severity index. Alimentary Pharmacology & Therapeutics, 18(1), 141–150.	Mearin, F., Lacy, B. E., Chang, L., et al. (2016). Bowel disorders. Gastroenterology. Published online June 2016 by the Rome Foundation.
Εναλλακτικές ονομασίες	GERD-HRQL, GERD-HRQoL	GCSI	Rome IV IBS, Rome Criteria
Συναφείς	4	4	4
Σύνοψη	The GERD Health-Related Quality of Life Scale (GERD-HRQL) is a concise, validated patient-reported outcome measure for assessing the symptomatic and functional impact of gastroesophageal reflux disease (GERD). Developed by Velanovich and colleagues in 1996, the 9-item GERD-HRQL measures heartburn frequency and severity, regurgitation, and impact on sleep and medication use. The scale is highly responsive to proton pump inhibitor (PPI) therapy and is widely used in GERD trials and clinical practice.	The Gastroparesis Cardinal Symptom Index (GCSI) is a validated, patient-reported outcome measure specifically designed to assess symptom severity in gastroparesis. Developed by Revicki and colleagues in 2003, the GCSI captures the three cardinal symptom clusters of gastroparesis: nausea and vomiting, postprandial fullness, and early satiety, plus bloating and stomach distension. The 9-item questionnaire is responsive to treatment changes and is increasingly used in clinical trials and practice to monitor gastroparesis progression and therapy response.	The Rome IV criteria are the internationally accepted diagnostic standard for irritable bowel syndrome (IBS), published in 2016 by the Rome Foundation. These criteria define IBS as recurrent abdominal pain (≥1 day per week for ≥3 months) associated with altered bowel habits, without structural or biochemical abnormalities. IBS is subtyped into four patterns—IBS-constipation predominant (IBS-C), IBS-diarrhea predominant (IBS-D), IBS-mixed (IBS-M), and IBS-unclassified (IBS-U)—based on stool consistency patterns.